What BPC-157 is, why it appears in tissue-model research, and where the evidence stops.
BPC-157 is a synthetic 15-amino-acid peptide commonly described in the literature as a stable gastric pentadecapeptide. Most published work is preclinical and uses cell systems or animal injury models.
What researchers examine
Experimental studies have explored angiogenesis, endothelial signaling, granulation tissue, tendon models, and gastrointestinal injury models. An early in vivo paper compared new-vessel and granulation-tissue formation across BPC-157 and several established gastroprotective agents. More recent mechanistic work continues to investigate signaling pathways, but this does not establish a validated human use.
How to interpret the evidence
Animal wound models are not consumer benefit claims. Outcomes depend on species, injury method, route, timing, and material identity. Human safety, pharmacokinetics, reproducibility, and clinical efficacy have not been established by the cited work. Researchers should also verify the complete sequence, salt or counterion, purity method, and analytical report rather than relying on the short name BPC-157.
Primary source
Research-use notice: For laboratory research use only. Not for human or veterinary use, ingestion, injection, therapeutic, diagnostic, or clinical use. This educational material summarizes research context; it is not medical advice and does not establish safety, efficacy, identity, purity, or suitability for any use.